New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting

Ariane Groth, Alexei V. Salnikov, Sabine Ottinger, Jury Gladkich, Li Liu, Georgios Kallifatidis, Olga Salnikova, Eduard Ryschich, Nathalia Giese, Thomas Giese, Frank Momburg, Markus W. Büchler, Gerhard Moldenhauer, Ingrid Herr

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: To enhance T-cell responsiveness toward cancer cells, we overexpressed TRAIL in lymphocytes, as this death ligand induces tumor-specific apoptosis. To increase contact time of lymphocytes with tumor cells and thereby of TRAIL with its death receptors, lymphocytes were linked to the CD3 arm of bispecific antibody EpCAMxCD3, to guide the lymphocytes to tumor cells positive for the cancer stem cell marker EpCAM/ESA. Experimental Design: Lymphocytes were transduced with TRAIL lentivirus and the antitumor effect in presence and absence of EpCAMxCD3 was evaluated in vitro and in xenograft studies using epithelial cell adhesion molecule (EpCAM)-positive pancreatic and prostate cancer cells. Results: Compared with control lymphocytes, TRAIL-lymphocytes increased cytotoxicity and further induced expression of several apoptosis-related molecules. Cotransplantation of TRAIL-lymphocytes and tumor cells in mice or peritumoral injection of TRAIL-lymphocytes in larger xenografts retarded growth and induced apoptosis. Combination of TRAIL-lymphocytes with EpCAMxCD3 potentiated tumor eradication by enhancing antiapoptotic and antiproliferative signaling and by decreasing tumor vasculature. Intratumoral cyst formation was involved and associated with enhanced chemokine secretion and infiltration of mouse macrophages, suggesting contribution of an inflammatory host response. Most importantly, tumorigenicity of pancreatic cancer cells with cancer stem cell features resistant to conventional chemotherapy was strongly reduced. Conclusions: This gene-immunotherapeutic approach may be a new tool to support endogenous immuneresponses toward cancer even in its advanced stages.

Original languageEnglish (US)
Pages (from-to)1028-1038
Number of pages11
JournalClinical Cancer Research
Volume18
Issue number4
DOIs
StatePublished - Feb 15 2012

Fingerprint

Bispecific Antibodies
Immunotherapy
Lymphocytes
Genes
Neoplasms
Neoplastic Stem Cells
Apoptosis
Pancreatic Neoplasms
Heterografts
Death Domain Receptors
Lentivirus
Chemokines
Cysts
Prostatic Neoplasms
Arm
Research Design
Macrophages

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting. / Groth, Ariane; Salnikov, Alexei V.; Ottinger, Sabine; Gladkich, Jury; Liu, Li; Kallifatidis, Georgios; Salnikova, Olga; Ryschich, Eduard; Giese, Nathalia; Giese, Thomas; Momburg, Frank; Büchler, Markus W.; Moldenhauer, Gerhard; Herr, Ingrid.

In: Clinical Cancer Research, Vol. 18, No. 4, 15.02.2012, p. 1028-1038.

Research output: Contribution to journalArticle

Groth, A, Salnikov, AV, Ottinger, S, Gladkich, J, Liu, L, Kallifatidis, G, Salnikova, O, Ryschich, E, Giese, N, Giese, T, Momburg, F, Büchler, MW, Moldenhauer, G & Herr, I 2012, 'New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting', Clinical Cancer Research, vol. 18, no. 4, pp. 1028-1038. https://doi.org/10.1158/1078-0432.CCR-11-2767
Groth, Ariane ; Salnikov, Alexei V. ; Ottinger, Sabine ; Gladkich, Jury ; Liu, Li ; Kallifatidis, Georgios ; Salnikova, Olga ; Ryschich, Eduard ; Giese, Nathalia ; Giese, Thomas ; Momburg, Frank ; Büchler, Markus W. ; Moldenhauer, Gerhard ; Herr, Ingrid. / New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 4. pp. 1028-1038.
@article{7ff6c8b63b0144cfa954c458da76034e,
title = "New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting",
abstract = "Purpose: To enhance T-cell responsiveness toward cancer cells, we overexpressed TRAIL in lymphocytes, as this death ligand induces tumor-specific apoptosis. To increase contact time of lymphocytes with tumor cells and thereby of TRAIL with its death receptors, lymphocytes were linked to the CD3 arm of bispecific antibody EpCAMxCD3, to guide the lymphocytes to tumor cells positive for the cancer stem cell marker EpCAM/ESA. Experimental Design: Lymphocytes were transduced with TRAIL lentivirus and the antitumor effect in presence and absence of EpCAMxCD3 was evaluated in vitro and in xenograft studies using epithelial cell adhesion molecule (EpCAM)-positive pancreatic and prostate cancer cells. Results: Compared with control lymphocytes, TRAIL-lymphocytes increased cytotoxicity and further induced expression of several apoptosis-related molecules. Cotransplantation of TRAIL-lymphocytes and tumor cells in mice or peritumoral injection of TRAIL-lymphocytes in larger xenografts retarded growth and induced apoptosis. Combination of TRAIL-lymphocytes with EpCAMxCD3 potentiated tumor eradication by enhancing antiapoptotic and antiproliferative signaling and by decreasing tumor vasculature. Intratumoral cyst formation was involved and associated with enhanced chemokine secretion and infiltration of mouse macrophages, suggesting contribution of an inflammatory host response. Most importantly, tumorigenicity of pancreatic cancer cells with cancer stem cell features resistant to conventional chemotherapy was strongly reduced. Conclusions: This gene-immunotherapeutic approach may be a new tool to support endogenous immuneresponses toward cancer even in its advanced stages.",
author = "Ariane Groth and Salnikov, {Alexei V.} and Sabine Ottinger and Jury Gladkich and Li Liu and Georgios Kallifatidis and Olga Salnikova and Eduard Ryschich and Nathalia Giese and Thomas Giese and Frank Momburg and B{\"u}chler, {Markus W.} and Gerhard Moldenhauer and Ingrid Herr",
year = "2012",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-11-2767",
language = "English (US)",
volume = "18",
pages = "1028--1038",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting

AU - Groth, Ariane

AU - Salnikov, Alexei V.

AU - Ottinger, Sabine

AU - Gladkich, Jury

AU - Liu, Li

AU - Kallifatidis, Georgios

AU - Salnikova, Olga

AU - Ryschich, Eduard

AU - Giese, Nathalia

AU - Giese, Thomas

AU - Momburg, Frank

AU - Büchler, Markus W.

AU - Moldenhauer, Gerhard

AU - Herr, Ingrid

PY - 2012/2/15

Y1 - 2012/2/15

N2 - Purpose: To enhance T-cell responsiveness toward cancer cells, we overexpressed TRAIL in lymphocytes, as this death ligand induces tumor-specific apoptosis. To increase contact time of lymphocytes with tumor cells and thereby of TRAIL with its death receptors, lymphocytes were linked to the CD3 arm of bispecific antibody EpCAMxCD3, to guide the lymphocytes to tumor cells positive for the cancer stem cell marker EpCAM/ESA. Experimental Design: Lymphocytes were transduced with TRAIL lentivirus and the antitumor effect in presence and absence of EpCAMxCD3 was evaluated in vitro and in xenograft studies using epithelial cell adhesion molecule (EpCAM)-positive pancreatic and prostate cancer cells. Results: Compared with control lymphocytes, TRAIL-lymphocytes increased cytotoxicity and further induced expression of several apoptosis-related molecules. Cotransplantation of TRAIL-lymphocytes and tumor cells in mice or peritumoral injection of TRAIL-lymphocytes in larger xenografts retarded growth and induced apoptosis. Combination of TRAIL-lymphocytes with EpCAMxCD3 potentiated tumor eradication by enhancing antiapoptotic and antiproliferative signaling and by decreasing tumor vasculature. Intratumoral cyst formation was involved and associated with enhanced chemokine secretion and infiltration of mouse macrophages, suggesting contribution of an inflammatory host response. Most importantly, tumorigenicity of pancreatic cancer cells with cancer stem cell features resistant to conventional chemotherapy was strongly reduced. Conclusions: This gene-immunotherapeutic approach may be a new tool to support endogenous immuneresponses toward cancer even in its advanced stages.

AB - Purpose: To enhance T-cell responsiveness toward cancer cells, we overexpressed TRAIL in lymphocytes, as this death ligand induces tumor-specific apoptosis. To increase contact time of lymphocytes with tumor cells and thereby of TRAIL with its death receptors, lymphocytes were linked to the CD3 arm of bispecific antibody EpCAMxCD3, to guide the lymphocytes to tumor cells positive for the cancer stem cell marker EpCAM/ESA. Experimental Design: Lymphocytes were transduced with TRAIL lentivirus and the antitumor effect in presence and absence of EpCAMxCD3 was evaluated in vitro and in xenograft studies using epithelial cell adhesion molecule (EpCAM)-positive pancreatic and prostate cancer cells. Results: Compared with control lymphocytes, TRAIL-lymphocytes increased cytotoxicity and further induced expression of several apoptosis-related molecules. Cotransplantation of TRAIL-lymphocytes and tumor cells in mice or peritumoral injection of TRAIL-lymphocytes in larger xenografts retarded growth and induced apoptosis. Combination of TRAIL-lymphocytes with EpCAMxCD3 potentiated tumor eradication by enhancing antiapoptotic and antiproliferative signaling and by decreasing tumor vasculature. Intratumoral cyst formation was involved and associated with enhanced chemokine secretion and infiltration of mouse macrophages, suggesting contribution of an inflammatory host response. Most importantly, tumorigenicity of pancreatic cancer cells with cancer stem cell features resistant to conventional chemotherapy was strongly reduced. Conclusions: This gene-immunotherapeutic approach may be a new tool to support endogenous immuneresponses toward cancer even in its advanced stages.

UR - http://www.scopus.com/inward/record.url?scp=84863132749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863132749&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-2767

DO - 10.1158/1078-0432.CCR-11-2767

M3 - Article

VL - 18

SP - 1028

EP - 1038

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -